Make Informed Investment Decisions with Affordable Access to Experts
Understanding Disease Management in Systemic Mastocytosis - A Look at Pipeline Products from Blueprint & DecipheraTicker(s): BPMC, DCPH
Name: Dr John Mascarenhas - MD
Institution: Mount Sinai
- Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai.
- Currently manages 40-50 patients with Systemic mastocytosis including ISM and ASM.
- PI of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC) and has served as PI/Study Chair of multiple early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML.
Please describe your clinical practice; roughly how many patients with Systemic mastocytosis do you currently manage?Added By: c_admin
Do you currently prescribe Midostaurin (Rydapt)?Added By: c_admin
What is your current first-line therapy for this disease?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.